DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1603)

Dyslipidemia | Landscape & Forecast | Disease Landscape & Forecast

Dyslipidemia | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease. With respect to lipid-modifying therapies, the greatest commercial success has come via agents reducing low-density lipoprotein (LDL) cholesterol, but research and development focusing on triglycerides, high-density lipoprotein (HDL) cholesterol, and other novel biomarkers is ongoing, all with the aim of ultimately providing CV benefits. During the 2016-2026 forecast period, the dyslipidemia market is expected to have two distinct phases: (1) early contraction due largely to the genericization of the dominant statin class, and ( 2) marked growth owing to the emergence of keenly awaited novel therapies, including Amgen’s Repatha, Sanofi/Regeneron Pharmaceuticals’ Praluent, The Medicine Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, AstraZeneca’s Epanova, Kowa Pharmaceuticals’ Parmodia, and Resverlogix’s apabetalone.
Questions Answered:

What impact will the genericization of AstraZeneca’s Crestor (rosuvastatin) and Merck’s Zetia/Ezetrol (ezetimibe) and Vytorin/Inegy (ezetimibe/simvastatin) have on the dyslipidemia market?
How will CV outcomes data for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and omega-3 fatty acid compounds affect the market?
How will the anticipated launches of novel oral products, including Esperion Therapeutics’ bempedoic acid, Resverlogix’s apabetalone, and Dalcor’s dalcetrapib, affect the use of the PCSK9 inhibitors? Which products will achieve the greatest use and why?
What impact will the anticipated launch of Kowa’s pemafibrate and AstraZeneca’s Epanova have on the management of hypertriglyceridemia?

Product Description:
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

  • Pub Date: September 2017
  • Author(s): Tim Blackstock, MB, ChB, MPhil

Request report

Related reports:
You may also be interested in: